Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Tarasova Website

Nadya I. Tarasova, Ph.D.

Selected Publications

1)  Zhao Y, Zeng C, Tarasova NI, Chasovskikh S, Dritschilo A, Timofeeva OA.
A new role for STAT3 as a regulator of chromatin topology.
Transcription. 4, 2013.
[Journal]
2)  Khavrutskii L, Yeh J, Timofeeva O, Tarasov S, Pritt S, Stefanisko K, Tarasova N.
Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis.
J. Vis. Exp. 78: e50541, 2013.
Full Text Article. [Journal]
3)  Timofeeva OA, Tarasova NI, Zhang X, Chasovskikh S, Cheema AK, Wang H, Brown ML, Dritschilo A.
STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain.
Proc. Natl. Acad. Sci. U.S.A. 2013.
[Journal]
4)  Timofeeva OA, Tarasova NI.
Alternative ways of modulating JAK-STAT pathway: Looking beyond phosphorylation.
JAKSTAT. 1: 274-284, 2012.
[Journal]
5)  Tarasov SG, Gaponenko V, Howard OM, Chen Y, Oppenheim JJ, Dyba MA, Subramaniam S, Lee Y, Michejda C, Tarasova NI.
Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles.
Proc. Natl. Acad. Sci. U.S.A. 108: 9798-803, 2011.
[Journal]
6)  Timofeeva OA, Chasovskikh S, Lonskaya I, Tarasova NI, Khavrutskii L, Tarasov SG, Zhang X, Korostyshevskiy VR, Cheema A, Zhang L, Dakshanamurthy S, Brown ML, Dritschilo A.
Mechanisms of Unphosphorylated STAT3 Transcription Factor Binding to DNA.
J. Biol. Chem. 287: 14192-200, 2012.
[Journal]
7)  Johannessen L, Remsberg J, Gaponenko V, Adams KM, Barchi JJ, Tarasov SG, Jiang S, Tarasova NI.
Peptide structure stabilization by membrane anchoring and its general applicability to the development of potent cell-permeable inhibitors.
Chembiochem. 12: 914-21, 2011.
[Journal]
8)  Lee Y, Chen Y, Tarasova NI, Gaponenko V.
The structure of monomeric components of self-assembling CXCR4 antagonists determines the architecture of resulting nanostructures.
Nanotechnology. 22: 505101, 2011.
[Journal]
9)  Tanigawa S, Wang H, Yang Y, Sharma N, Tarasova N, Ajima R, Yamaguchi TP, Rodriguez LG, Perantoni AO.
Wnt4 induces nephronic tubules in metanephric mesenchyme by a non-canonical mechanism.
Dev Biol. 352: 58-69, 2011.
[Journal]
10)  Wang H, Yang Y, Sharma N, Tarasova NI, Timofeeva OA, Winkler-Pickett RT, Tanigawa S, Perantoni AO.
STAT1 activation regulates proliferation and differentiation of renal progenitors.
Cell Signal. 22: 1717-26, 2010.
[Journal]
11)  Polgar O, Ierano C, Tamaki A, Stanley B, Ward Y, Xia D, Tarasova N, Robey RW, Bates SE.
Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.
Biochemistry. 49: 2235-45, 2010.
[Journal]
12)  Timofeeva OA, Gaponenko V, Lockett SJ, Tarasov SG, Jiang S, Michejda CJ, Perantoni AO, Tarasova NI.
Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target.
ACS Chem. Biol. 2: 799-809, 2007.
Full Text Article. [Journal]
13)  Moody TW, Pradhan T, Mantey SA, Jensen RT, Dyba M, Moody D, Tarasova NI, Michejda CJ.
Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.
Life Sci. 82: 855-61, 2008.
[Journal]
14)  Remsberg J, Lou H, Tarasov S, Dean M, Tarasova N.
Structural Analogues of Smoothened Intracellular Loops as Potent Inhibitors of Hedgehog Pathway and Cancer Cell Growth.
J.Med. Chem. 50: 4534-4538, 2007.
Full Text Article. [Journal]
15)  Hariprakasha H, Kosakowska-Cholody T, Meyer C, Cholody W, Stinson S, Tarasova N, Michejda C.
Optimization of naphthylimido-imidazoacridone with potent anti-tumor activity leading to clinical candidate HKH40A (RTA 502).
J. Med. Chem. 50: 5557-5560, 2007.
Full Text Article. [Journal]
16)  Moody DL, Dyba M, Kosakowska-Cholody T, Tarasova NI, Michejda CJ.
Synthesis and biological activity of 5-aza-ellipticine derivatives.
Bioorg. Med. Chem. Lett. 17: 2380-4, 2007.
[Journal]
17)  Tarasova NI, Seth R, Tarasov SG, Kosakowska-Cholody T, Hrycyna CA, Gottesman MM, Michejda CJ.
Transmembrane inhibitors of P-glycoprotein, an ABC transporter.
J Med Chem. 48: 3768-75, 2005.
[Journal]
18)  Dyba M, Tarasova NI, Michejda CJ.
Small molecule toxins targeting tumor receptors.
Curr Pharm Des. 10: 2311-34, 2004.
[Journal]
19)  Moody TW, Czerwinski G, Tarasova NI, Moody DL, Michejda CJ.
The development of VIP-ellipticine conjugates.
Regul Pept. 123: 187-92, 2004.
[Journal]
20)  Polgar O, Robey RW, Morisaki K, Dean M, Michejda C, Sauna ZE, Ambudkar SV, Tarasova N, Bates SE.
Mutational analysis of ABCG2: role of the GXXXG motif.
Biochemistry. 43: 9448-56, 2004.
[Journal]
21)  Singh P, Lu X, Cobb S, Miller BT, Tarasova N, Varro A, Owlia A.
Progastrin1-80 stimulates growth of intestinal epithelial cells in vitro via high-affinity binding sites.
Am J Physiol Gastrointest Liver Physiol. 284: G328-39, 2003.
[Journal]
22)  Cobb S, Wood T, Tessarollo L, Velasco M, Given R, Varro A, Tarasova N, Singh P.
Deletion of functional gastrin gene markedly increases colon carcinogenesis in response to azoxymethane in mice.
Gastroenterology. 123: 516-30, 2002.
[Journal]
23)  Moody TW, Czerwinski G, Tarasova NI, Michejda CJ.
VIP-ellipticine derivatives inhibit the growth of breast cancer cells.
Life Sci. 71: 1005-14, 2002.
[Journal]
24)  Marko D, Merz KH, Kunz C, Müller A, Tarasova N, Eisenbrand G.
Intracellular localization of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine in membrane structures impeding the inhibition of cytosolic cyclic AMP-specific phosphodiesterase.
Biochem Pharmacol. 63: 669-76, 2002.
[Journal]
25)  Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ.
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.
Am J Pathol. 158: 905-19, 2001.
[Journal]
26)  Fujinaga M, Cherney MM, Tarasova NI, Bartlett PA, Hanson JE, James MN.
Structural study of the complex between human pepsin and a phosphorus-containing peptidic -transition-state analog.
Acta Crystallogr D Biol Crystallogr. 56 ( Pt 3): 272-9, 2000.
[Journal]
27)  Tarasova NI, Rice WG, Michejda CJ.
Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions.
J Biol Chem. 274: 34911-5, 1999.
[Journal]
28)  Saillan-Barreau C, Dufresne M, Clerc P, Sanchez D, Corominola H, Moriscot C, Guy-Crotte O, Escrieut C, Vaysse N, Gomis R, Tarasova N, Fourmy D.
Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas.
Diabetes. 48: 2015-21, 1999.
[Journal]
29)  Stauber RH, Rulong S, Palm G, Tarasova NI.
Direct visualization of HIV-1 entry: mechanisms and role of cell surface receptors.
Biochem Biophys Res Commun. 258: 695-702, 1999.
[Journal]
30)  Czerwinski G, Tarasova NI, Michejda CJ.
Cytotoxic agents directed to peptide hormone receptors: defining the requirements for a successful drug.
Proc Natl Acad Sci U S A. 95: 11520-5, 1998.
[Journal]
31)  Howard OM, Korte T, Tarasova NI, Grimm M, Turpin JA, Rice WG, Michejda CJ, Blumenthal R, Oppenheim JJ.
Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function.
J Leukoc Biol. 64: 6-13, 1998.
[Journal]
32)  Tarasova NI, Stauber RH, Michejda CJ.
Spontaneous and ligand-induced trafficking of CXC-chemokine receptor 4.
J Biol Chem. 273: 15883-6, 1998.
[Journal]
33)  Bateman KS, Chernaia MM, Tarasova NI, James MN.
Crystal structure of human pepsinogen A.
Adv Exp Med Biol. 436: 259-63, 1998.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 3/31/2014.